ReviewNature reviews. Gastroenterology & hepatology2019
IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting.
Review in Nature reviews. Gastroenterology & hepatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 270 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
270 citing papers in PubMed, 7 syntheses or guidelines pooled it, 462 citations in OpenAlex.
- Integration of GWAS and single-cell analysis for psoriasis identifies disease-associated cell subtypes and therapeutic targets.Nature communications · 2026Pooled it
- Pooled it
- Role of interleukin 17 and T helper cells 17 cells as a new immune target and signalling in the pathogenesis and treatment of autoimmune thyroid diseases.Annals of medicine · 2025Pooled it
- IL-23p19 Antagonists vs Ustekinumab for Treatment of Crohn's Disease: A Meta-Analysis of Randomized Controlled Trials.The American journal of gastroenterology · 2025Pooled it
- Interlukin-23 inhibitors as an induction and maintenance therapy for moderate to severe ulcerative colitis: a systematic review and meta‑analysis of randomized controlled trials.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Pooled it
- Efficacy and Safety of IL-12/23 and IL-23 Inhibitors for Crohn's Disease: Systematic Review and Meta-Analysis.Digestive diseases and sciences · 2023Pooled it
- A bibliometric and visual analysis of the use of ustekinumab in Crohn's disease using CiteSpace.Frontiers in pharmacology · 2023Pooled it
- Serum and Histologic Eosinophilia as a Predictive Biomarker of Response to Mirikizumab in Ulcerative Colitis.Inflammatory bowel diseases · 2026Trial
- Trial
- Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.Signal transduction and targeted therapy · 2026Review
- Selective IL-23 inhibitors in ulcerative colitis: current evidence and perspectives for multimodal personalized treatment: a narrative review.Journal of gastroenterology · 2026Review
- Post-Marketing Safety Profile of Mirikizumab: A Multi-Database Pharmacovigilance Study Using FAERS and JADER with IL-23 Inhibitor Class Comparison.Bioengineering (Basel, Switzerland) · 2026Article
- Autoantibodies Drive Fcγ Receptor-Dependent Colon Inflammation During Immune Checkpoint Blockade.bioRxiv : the preprint server for biology · 2026Article
- Ulcerative Colitis after Administration of Dupilumab, an Anti-interleukin-4 Receptor Subunit α Monoclonal Antibody.Internal medicine (Tokyo, Japan) · 2026Article
- Systemic Cytokine Patterns and Histologic Disease Spectrum in Inflammatory Bowel Disease.Current issues in molecular biology · 2026Article
- Organoid phenotypic screening identified glycyrrhizin that confers protection against tumor necrosis factor-induced cell death.Stem cell reports · 2026Article
- Systemic Immune Signatures of Endoscopic-Histologic Discordance in Inflammatory Bowel Disease: A Pilot Study.Journal of clinical medicine · 2026Article
- Long-term drug persistence and clinical outcomes of ustekinumab in Crohn's disease: a multicenter real-world study from the Hokkaido phoenix cohort.Crohn's & colitis 360 · 2026Article
- Real-world effectiveness of guselkumab for induction of remission in Crohn's disease: a prospective multicenter cohort study with propensity score-matched comparison to risankizumab.Crohn's & colitis 360 · 2026Article
- CD64 binding potential does not translate into enhanced therapeutic efficacy for anti-IL-23 antibodies under physiologically relevant conditions.Molecular medicine (Cambridge, Mass.) · 2026Article
210 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IL-12 and IL-23 are closely related cytokines with important roles in the regulation of tissue inflammation. Converging evidence from studies in mice, human observational studies and population genetics supports the importance of these cytokines in the regulation of mucosal inflammation in the gut in particular. Ustekinumab, a therapeutic antibody targeting both cytokines is now widely licensed for the treatment of Crohn's disease, including in Europe, the USA, Canada and Japan, whilst agents targeting IL-23 specifically are in late-phase clinical trials. We review the emerging understanding of the biology of IL-12 and IL-23, as well as that of their major downstream cytokines, including IL-17. In particular, we discuss how their biology has influenced the development of clinical trials and therapeutic strategies in IBD, as well as how findings from clinical trials, at times surprising, have in turn refocused our understanding of the underlying biology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.